Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages

NCT04570085 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT04570085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04570085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages
Lead sponsor
University Hospital, Lille
Phase
Phase 3
Overall status
Recruiting
Start date
March 1, 2021
Completion date
December 31, 2027
Enrollment
248 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease